A065660 Stock Overview
A bio-venture company, engages in the research, development, and commercialization of cell therapy products using adipose-derived stem cells in South Korea and internationally.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Anterogen.Co.,Ltd. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | ₩15,470.00 |
52 Week High | ₩19,150.00 |
52 Week Low | ₩12,300.00 |
Beta | 0.32 |
11 Month Change | -0.51% |
3 Month Change | -15.33% |
1 Year Change | -1.90% |
33 Year Change | -76.56% |
5 Year Change | -65.62% |
Change since IPO | -60.43% |
Recent News & Updates
Shareholder Returns
A065660 | KR Biotechs | KR Market | |
---|---|---|---|
7D | 6.3% | -0.1% | -0.01% |
1Y | -1.9% | 22.1% | 5.0% |
Return vs Industry: A065660 underperformed the KR Biotechs industry which returned 22.2% over the past year.
Return vs Market: A065660 underperformed the KR Market which returned 5.8% over the past year.
Price Volatility
A065660 volatility | |
---|---|
A065660 Average Weekly Movement | 10.5% |
Biotechs Industry Average Movement | 7.8% |
Market Average Movement | 5.0% |
10% most volatile stocks in KR Market | 11.1% |
10% least volatile stocks in KR Market | 2.3% |
Stable Share Price: A065660 has not had significant price volatility in the past 3 months.
Volatility Over Time: A065660's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of KR stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2000 | n/a | Seong-Gu Lee | anterogen.com |
Anterogen Co.,Ltd., a bio-venture company, engages in the research, development, and commercialization of cell therapy products using adipose-derived stem cells in South Korea and internationally. The company offers medicines, including Cupistem injection, an adipose stem cell product that is used for the treatment of Crohn’s fistula; Queencell, a stromal vascular fraction used for the regeneration of subcutaneous adipose tissue; and Remodulin injection, a medicine for the treatment of pulmonary arterial hypertension.
Anterogen.Co.,Ltd. Fundamentals Summary
A065660 fundamental statistics | |
---|---|
Market cap | ₩150.54b |
Earnings (TTM) | -₩3.45b |
Revenue (TTM) | ₩6.49b |
23.2x
P/S Ratio-43.6x
P/E RatioIs A065660 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
A065660 income statement (TTM) | |
---|---|
Revenue | ₩6.49b |
Cost of Revenue | ₩3.72b |
Gross Profit | ₩2.77b |
Other Expenses | ₩6.22b |
Earnings | -₩3.45b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -354.49 |
Gross Margin | 42.65% |
Net Profit Margin | -53.15% |
Debt/Equity Ratio | 0% |
How did A065660 perform over the long term?
See historical performance and comparison